- Home
- SAVA vs OKYO Comparison
SAVA vs OKYO Comparison
Compare SAVA & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- OKYO
- Stock Information
- Founded
- SAVA 1998
- OKYO 2007
- Country
- SAVA United States
- OKYO United Kingdom
- Employees
- SAVA N/A
- OKYO N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- OKYO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAVA Health Care
- OKYO Health Care
- Exchange
- SAVA Nasdaq
- OKYO Nasdaq
- Market Cap
- SAVA 102.4M
- OKYO 85.0M
- IPO Year
- SAVA N/A
- OKYO 2022
- Fundamental
- Price
- SAVA $3.63
- OKYO $2.05
- Analyst Decision
- SAVA Hold
- OKYO Strong Buy
- Analyst Count
- SAVA 1
- OKYO 1
- Target Price
- SAVA $2.00
- OKYO $7.00
- AVG Volume (30 Days)
- SAVA 4.9M
- OKYO 92.3K
- Earning Date
- SAVA 11-06-2025
- OKYO 07-18-2025
- Dividend Yield
- SAVA N/A
- OKYO N/A
- EPS Growth
- SAVA N/A
- OKYO N/A
- EPS
- SAVA N/A
- OKYO N/A
- Revenue
- SAVA N/A
- OKYO N/A
- Revenue This Year
- SAVA N/A
- OKYO N/A
- Revenue Next Year
- SAVA N/A
- OKYO N/A
- P/E Ratio
- SAVA N/A
- OKYO N/A
- Revenue Growth
- SAVA N/A
- OKYO N/A
- 52 Week Low
- SAVA $1.15
- OKYO $0.90
- 52 Week High
- SAVA $33.98
- OKYO $3.35
- Technical
- Relative Strength Index (RSI)
- SAVA 72.05
- OKYO 42.40
- Support Level
- SAVA $2.85
- OKYO $2.02
- Resistance Level
- SAVA $3.66
- OKYO $2.24
- Average True Range (ATR)
- SAVA 0.34
- OKYO 0.18
- MACD
- SAVA 0.10
- OKYO 0.01
- Stochastic Oscillator
- SAVA 92.90
- OKYO 26.09
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.